25 XP   0   0   10

Opthea Ltd
Buy, Hold or Sell?

Let's analyse Opthea together

PenkeI guess you are interested in Opthea Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Opthea Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Opthea Ltd

I send you an email if I find something interesting about Opthea Ltd.

Quick analysis of Opthea (30 sec.)










What can you expect buying and holding a share of Opthea? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$-0.01
Expected worth in 1 year
A$-0.33
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
A$-0.32
Return On Investment
-50.7%

For what price can you sell your share?

Current Price per Share
A$0.64
Expected price per share
A$0.59 - A$0.74938214285714
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Opthea (5 min.)




Live pricePrice per Share (EOD)

A$0.64

Intrinsic Value Per Share

A$-3.01 - A$-1.16

Total Value Per Share

A$-3.02 - A$-1.17

2. Growth of Opthea (5 min.)




Is Opthea growing?

Current yearPrevious yearGrowGrow %
How rich?-$3.7m$31.1m-$34.9m-933.1%

How much money is Opthea making?

Current yearPrevious yearGrowGrow %
Making money-$92.6m-$60.3m-$32.3m-34.9%
Net Profit Margin-131,469.7%-102,353.7%--

How much money comes from the company's main activities?

3. Financial Health of Opthea (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#947 / 1050

Most Revenue
#641 / 1050

Most Profit
#997 / 1050

Most Efficient
#1034 / 1050
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Opthea? (5 min.)

Welcome investor! Opthea's management wants to use your money to grow the business. In return you get a share of Opthea.

What can you expect buying and holding a share of Opthea?

First you should know what it really means to hold a share of Opthea. And how you can make/lose money.

Speculation

The Price per Share of Opthea is A$0.64. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Opthea.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Opthea, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$-0.01. Based on the TTM, the Book Value Change Per Share is A$-0.08 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Opthea.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.14-21.8%-0.14-21.8%-0.09-14.2%-0.06-9.7%-0.04-5.5%
Usd Book Value Change Per Share-0.05-8.2%-0.05-8.2%-0.09-13.4%-0.01-1.0%0.00-0.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.05-8.2%-0.05-8.2%-0.09-13.4%-0.01-1.0%0.00-0.3%
Usd Price Per Share0.36-0.36-0.71-0.78-0.53-
Price to Earnings Ratio-2.56--2.56--7.86--29.16--35.17-
Price-to-Total Gains Ratio-6.78--6.78--8.35--1.54--9.74-
Price to Book Ratio-63.30--63.30-15.20-2.79-8.77-
Price-to-Total Gains Ratio-6.78--6.78--8.35--1.54--9.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.415936
Number of shares2404
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.05-0.01
Usd Total Gains Per Share-0.05-0.01
Gains per Quarter (2404 shares)-126.67-15.93
Gains per Year (2404 shares)-506.66-63.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-507-5170-64-74
20-1013-10240-127-138
30-1520-15310-191-202
40-2027-20380-255-266
50-2533-25450-319-330
60-3040-30520-382-394
70-3547-35590-446-458
80-4053-40660-510-522
90-4560-45730-574-586
100-5067-50800-637-650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%5.028.00.015.2%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%17.016.00.051.5%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%4.00.029.012.1%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%18.015.00.054.5%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Opthea

About Opthea Ltd

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 "VEGFR-3", currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Fundamental data was last updated by Penke on 2024-02-28 09:46:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Opthea Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Opthea earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Opthea to the Biotechnology industry mean.
  • A Net Profit Margin of -131,469.7% means that $-1,314.70 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Opthea Ltd:

  • The MRQ is -131,469.7%. The company is making a huge loss. -2
  • The TTM is -131,469.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-131,469.7%TTM-131,469.7%0.0%
TTM-131,469.7%YOY-102,353.7%-29,116.1%
TTM-131,469.7%5Y-64,432.2%-67,037.6%
5Y-64,432.2%10Y-32,562.1%-31,870.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-131,469.7%-172.8%-131,296.9%
TTM-131,469.7%-213.8%-131,255.9%
YOY-102,353.7%-292.1%-102,061.6%
5Y-64,432.2%-479.2%-63,953.0%
10Y-32,562.1%-636.2%-31,925.9%
1.1.2. Return on Assets

Shows how efficient Opthea is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Opthea to the Biotechnology industry mean.
  • -144.5% Return on Assets means that Opthea generated $-1.44 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Opthea Ltd:

  • The MRQ is -144.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -144.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-144.5%TTM-144.5%0.0%
TTM-144.5%YOY-154.6%+10.1%
TTM-144.5%5Y-82.1%-62.4%
5Y-82.1%10Y-55.0%-27.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-144.5%-12.5%-132.0%
TTM-144.5%-12.2%-132.3%
YOY-154.6%-11.3%-143.3%
5Y-82.1%-13.7%-68.4%
10Y-55.0%-15.4%-39.6%
1.1.3. Return on Equity

Shows how efficient Opthea is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Opthea to the Biotechnology industry mean.
  • 0.0% Return on Equity means Opthea generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Opthea Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-193.5%+193.5%
TTM-5Y-63.9%+63.9%
5Y-63.9%10Y-48.6%-15.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.2%+16.2%
TTM--15.9%+15.9%
YOY-193.5%-14.4%-179.1%
5Y-63.9%-18.9%-45.0%
10Y-48.6%-19.8%-28.8%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Opthea Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Opthea is operating .

  • Measures how much profit Opthea makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Opthea to the Biotechnology industry mean.
  • An Operating Margin of -135,415.3% means the company generated $-1,354.15  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Opthea Ltd:

  • The MRQ is -135,415.3%. The company is operating very inefficient. -2
  • The TTM is -135,415.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-135,415.3%TTM-135,415.3%0.0%
TTM-135,415.3%YOY-103,353.2%-32,062.1%
TTM-135,415.3%5Y-63,318.5%-72,096.8%
5Y-63,318.5%10Y-32,202.7%-31,115.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-135,415.3%-299.5%-135,115.8%
TTM-135,415.3%-222.2%-135,193.1%
YOY-103,353.2%-296.8%-103,056.4%
5Y-63,318.5%-469.0%-62,849.5%
10Y-32,202.7%-617.8%-31,584.9%
1.2.2. Operating Ratio

Measures how efficient Opthea is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1,386.46 means that the operating costs are $1,386.46 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Opthea Ltd:

  • The MRQ is 1,386.464. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1,386.464. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1,386.464TTM1,386.4640.000
TTM1,386.464YOY1,067.335+319.129
TTM1,386.4645Y681.869+704.595
5Y681.86910Y346.694+335.176
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1,386.4642.914+1,383.550
TTM1,386.4643.255+1,383.209
YOY1,067.3353.885+1,063.450
5Y681.8696.009+675.860
10Y346.6947.652+339.042
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Opthea Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Opthea is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.28 means the company has $5.28 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Opthea Ltd:

  • The MRQ is 5.276. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.276. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.276TTM5.2760.000
TTM5.276YOY4.975+0.301
TTM5.2765Y14.136-8.860
5Y14.13610Y12.774+1.363
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.2764.017+1.259
TTM5.2764.478+0.798
YOY4.9755.591-0.616
5Y14.1366.256+7.880
10Y12.7746.562+6.212
1.3.2. Quick Ratio

Measures if Opthea is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Opthea to the Biotechnology industry mean.
  • A Quick Ratio of 5.13 means the company can pay off $5.13 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Opthea Ltd:

  • The MRQ is 5.135. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.135. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.135TTM5.1350.000
TTM5.135YOY4.251+0.884
TTM5.1355Y12.314-7.180
5Y12.31410Y11.203+1.111
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.1353.585+1.550
TTM5.1354.182+0.953
YOY4.2515.485-1.234
5Y12.3146.116+6.198
10Y11.2036.375+4.828
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Opthea Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Opthea assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Opthea to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.06 means that Opthea assets are financed with 105.8% credit (debt) and the remaining percentage (100% - 105.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Opthea Ltd:

  • The MRQ is 1.058. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.058. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.058TTM1.0580.000
TTM1.058YOY0.201+0.857
TTM1.0585Y0.311+0.748
5Y0.31110Y0.214+0.097
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0580.332+0.726
TTM1.0580.331+0.727
YOY0.2010.262-0.061
5Y0.3110.370-0.059
10Y0.2140.380-0.166
1.4.2. Debt to Equity Ratio

Measures if Opthea is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Opthea to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Opthea Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.252-0.252
TTM-5Y0.119-0.119
5Y0.11910Y0.130-0.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.375-0.375
TTM-0.396-0.396
YOY0.2520.317-0.065
5Y0.1190.423-0.304
10Y0.1300.477-0.347
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Opthea Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Opthea generates.

  • Above 15 is considered overpriced but always compare Opthea to the Biotechnology industry mean.
  • A PE ratio of -2.56 means the investor is paying $-2.56 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Opthea Ltd:

  • The EOD is -2.976. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.558. Based on the earnings, the company is expensive. -2
  • The TTM is -2.558. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.976MRQ-2.558-0.419
MRQ-2.558TTM-2.5580.000
TTM-2.558YOY-7.855+5.297
TTM-2.5585Y-29.160+26.602
5Y-29.16010Y-35.167+6.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.976-2.631-0.345
MRQ-2.558-2.224-0.334
TTM-2.558-2.796+0.238
YOY-7.855-4.390-3.465
5Y-29.160-6.123-23.037
10Y-35.167-6.245-28.922
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Opthea Ltd:

  • The EOD is -3.516. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.022. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.022. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.516MRQ-3.022-0.495
MRQ-3.022TTM-3.0220.000
TTM-3.022YOY-10.218+7.196
TTM-3.0225Y-63.572+60.550
5Y-63.57210Y-56.005-7.568
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.516-3.503-0.013
MRQ-3.022-2.905-0.117
TTM-3.022-3.541+0.519
YOY-10.218-6.014-4.204
5Y-63.572-8.355-55.217
10Y-56.005-8.755-47.250
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Opthea is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -63.30 means the investor is paying $-63.30 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Opthea Ltd:

  • The EOD is -73.664. Based on the equity, the company is expensive. -2
  • The MRQ is -63.305. Based on the equity, the company is expensive. -2
  • The TTM is -63.305. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-73.664MRQ-63.305-10.359
MRQ-63.305TTM-63.3050.000
TTM-63.305YOY15.197-78.501
TTM-63.3055Y2.787-66.092
5Y2.78710Y8.767-5.980
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-73.6642.137-75.801
MRQ-63.3051.877-65.182
TTM-63.3052.117-65.422
YOY15.1973.059+12.138
5Y2.7873.595-0.808
10Y8.7673.961+4.806
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Opthea Ltd.

3.1. Funds holding Opthea Ltd

3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Opthea Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.081-0.0810%-0.132+62%-0.010-87%-0.003-96%
Book Value Per Share---0.009-0.0090%0.072-112%0.074-112%0.053-116%
Current Ratio--5.2765.2760%4.975+6%14.136-63%12.774-59%
Debt To Asset Ratio--1.0581.0580%0.201+427%0.311+241%0.214+394%
Debt To Equity Ratio----0%0.252-100%0.119-100%0.130-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.215-0.2150%-0.140-35%-0.096-55%-0.054-75%
Free Cash Flow Per Share---0.182-0.1820%-0.108-41%-0.079-57%-0.045-75%
Free Cash Flow To Equity Per Share--0.0700.0700%-0.107+253%0.020+252%0.016+351%
Gross Profit Margin--1.0001.0000%1.0000%1.0040%1.049-5%
Intrinsic Value_10Y_max---1.164--------
Intrinsic Value_10Y_min---3.009--------
Intrinsic Value_1Y_max---0.061--------
Intrinsic Value_1Y_min---0.167--------
Intrinsic Value_3Y_max---0.225--------
Intrinsic Value_3Y_min---0.621--------
Intrinsic Value_5Y_max---0.441--------
Intrinsic Value_5Y_min---1.203--------
Market Cap424196464.640+14%364543836.800364543836.8000%729087673.600-50%797356792.128-54%540850492.416-33%
Net Profit Margin---1314.697-1314.6970%-1023.537-22%-644.322-51%-325.621-75%
Operating Margin---1354.153-1354.1530%-1033.532-24%-633.185-53%-322.027-76%
Operating Ratio--1386.4641386.4640%1067.335+30%681.869+103%346.694+300%
Pb Ratio-73.664-16%-63.305-63.3050%15.197-517%2.787-2371%8.767-822%
Pe Ratio-2.976-16%-2.558-2.5580%-7.855+207%-29.160+1040%-35.167+1275%
Price Per Share0.640+14%0.5500.5500%1.100-50%1.203-54%0.816-33%
Price To Free Cash Flow Ratio-3.516-16%-3.022-3.0220%-10.218+238%-63.572+2004%-56.005+1753%
Price To Total Gains Ratio-7.894-16%-6.784-6.7840%-8.351+23%-1.535-77%-9.740+44%
Quick Ratio--5.1355.1350%4.251+21%12.314-58%11.203-54%
Return On Assets---1.445-1.4450%-1.546+7%-0.821-43%-0.550-62%
Return On Equity----0%-1.9350%-0.6390%-0.4860%
Total Gains Per Share---0.081-0.0810%-0.132+62%-0.010-87%-0.003-96%
Usd Book Value---3742480.995-3742480.9950%31180345.886-112%31692964.948-112%22841201.168-116%
Usd Book Value Change Per Share---0.053-0.0530%-0.086+62%-0.007-87%-0.002-96%
Usd Book Value Per Share---0.006-0.0060%0.047-112%0.048-112%0.034-116%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.140-0.1400%-0.091-35%-0.062-55%-0.035-75%
Usd Free Cash Flow---78397653.417-78397653.4170%-46371575.114-41%-33863815.614-57%-19468625.693-75%
Usd Free Cash Flow Per Share---0.118-0.1180%-0.070-41%-0.051-57%-0.029-75%
Usd Free Cash Flow To Equity Per Share--0.0460.0460%-0.070+253%0.013+252%0.010+351%
Usd Market Cap275685282.370+14%236917039.536236917039.5360%473834079.073-50%518202179.204-54%351498735.021-33%
Usd Price Per Share0.416+14%0.3570.3570%0.715-50%0.782-54%0.530-33%
Usd Profit---92624453.142-92624453.1420%-60322009.413-35%-39862874.834-57%-21872787.530-76%
Usd Revenue--70453.05970453.0590%58934.882+20%66788.533+5%307169.321-77%
Usd Total Gains Per Share---0.053-0.0530%-0.086+62%-0.007-87%-0.002-96%
 EOD+6 -2MRQTTM+0 -0YOY+14 -185Y+6 -2710Y+6 -27

4.2. Fundamental Score

Let's check the fundamental score of Opthea Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.976
Price to Book Ratio (EOD)Between0-1-73.664
Net Profit Margin (MRQ)Greater than0-1,314.697
Operating Margin (MRQ)Greater than0-1,354.153
Quick Ratio (MRQ)Greater than15.135
Current Ratio (MRQ)Greater than15.276
Debt to Asset Ratio (MRQ)Less than11.058
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.445
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Opthea Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.706
Ma 20Greater thanMa 500.596
Ma 50Greater thanMa 1000.550
Ma 100Greater thanMa 2000.465
OpenGreater thanClose0.700
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-06-302020-06-302021-06-302022-06-302023-06-30
Total Stockholder Equity 21,79422,73744,53190,755135,286-87,30947,977-53,736-5,759
Net Tangible Assets  31,12033,68964,80870,478135,286-87,30947,977-53,830-5,853
Net Invested Capital  31,12033,68964,80870,478135,286-87,30947,977-53,736-5,759
Net Interest Income  756-34721-349372-137235-10,470-10,235



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets98,641
Total Liabilities104,400
Total Stockholder Equity-5,759
 As reported
Total Liabilities 104,400
Total Stockholder Equity+ -5,759
Total Assets = 98,641

Assets

Total Assets98,641
Total Current Assets98,386
Long-term Assets255
Total Current Assets
Cash And Cash Equivalents 89,189
Net Receivables 6,563
Inventory -1,323
Other Current Assets 3,958
Total Current Assets  (as reported)98,386
Total Current Assets  (calculated)98,386
+/-0
Long-term Assets
Property Plant Equipment 201
Long-term Assets Other 54
Long-term Assets  (as reported)255
Long-term Assets  (calculated)255
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities18,648
Long-term Liabilities85,752
Total Stockholder Equity-5,759
Total Current Liabilities
Short-term Debt 97
Accounts payable 17,797
Other Current Liabilities 753
Total Current Liabilities  (as reported)18,648
Total Current Liabilities  (calculated)18,648
+/-0
Long-term Liabilities
Long term Debt Total 85,744
Other Liabilities 8
Long-term Liabilities  (as reported)85,752
Long-term Liabilities  (calculated)85,752
+/- 0
Total Stockholder Equity
Common Stock320,884
Retained Earnings -359,368
Accumulated Other Comprehensive Income 32,726
Total Stockholder Equity (as reported)-5,759
Total Stockholder Equity (calculated)-5,759
+/-0
Other
Capital Stock320,884
Cash And Equivalents77,122
Cash and Short Term Investments 89,189
Common Stock Shares Outstanding 351,560
Liabilities and Stockholders Equity 98,641
Net Debt -89,007
Net Invested Capital -5,759
Net Tangible Assets -5,853
Net Working Capital 79,738
Property Plant and Equipment Gross 201
Short Long Term Debt Total 182



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-301997-06-301996-06-301995-06-301994-06-301993-06-301992-06-301991-06-301990-06-301989-06-30
> Total Assets 
3,286
1,930
1,755
2,258
2,467
2,917
3,018
4,990
5,491
4,491
7,298
25,487
47,749
41,720
24,833
29,464
32,917
43,787
56,708
51,523
33,314
29,464
26,187
23,134
14,978
11,732
18,464
12,735
43,452
33,847
26,375
49,395
138,409
60,047
98,641
98,64160,047138,40949,39526,37533,84743,45212,73518,46411,73214,97823,13426,18729,46433,31451,52356,70843,78732,91729,46424,83341,72047,74925,4877,2984,4915,4914,9903,0182,9172,4672,2581,7551,9303,286
   > Total Current Assets 
1,824
471
301
811
825
908
911
2,831
3,170
2,196
5,063
14,398
25,890
20,223
10,054
12,457
19,163
21,118
41,317
45,041
31,817
27,438
23,933
18,595
12,294
9,397
16,814
12,431
42,520
33,213
25,837
49,003
138,118
59,908
98,386
98,38659,908138,11849,00325,83733,21342,52012,43116,8149,39712,29418,59523,93327,43831,81745,04141,31721,11819,16312,45710,05420,22325,89014,3985,0632,1963,1702,8319119088258113014711,824
       Cash And Cash Equivalents 
1,215
386
200
520
680
883
855
2,762
2,757
1,986
110
460
25,412
20,005
9,892
12,187
18,818
10,839
40,876
44,218
31,343
27,073
23,624
16,824
10,042
6,743
14,140
10,818
39,929
23,882
15,082
42,615
118,193
44,631
89,189
89,18944,631118,19342,61515,08223,88239,92910,81814,1406,74310,04216,82423,62427,07331,34344,21840,87610,83918,81812,1879,89220,00525,4124601101,9862,7572,7628558836805202003861,215
       Short-term Investments 
530
61
92
206
124
0
0
0
0
0
4,918
13,800
201
128
47
28
14
9,898
12
0
0
0
0
0
0
0
0
126
0
0
0
0
0
0
0
000000012600000000129,89814284712820113,8004,918000001242069261530
       Net Receivables 
79
24
9
85
21
25
56
69
413
210
35
113
252
57
64
62
181
83
266
514
383
304
223
1,695
332
390
180
165
391
289
207
195
5,538
6,557
6,563
6,5636,5575,5381952072893911651803903321,6952233043835142668318162645725211335210413695625218592479
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
25
24
33
52
180
150
298
163
309
91
61
86
76
1,920
2,264
2,494
1,321
2,201
9,042
10,548
479
19,162
8,720
3,958
3,9588,72019,16247910,5489,0422,2011,3212,4942,2641,920768661913091632981501805233242500000000000
   > Long-term Assets 
1,462
1,459
1,454
1,447
1,642
2,009
2,107
2,159
2,320
2,295
2,235
11,089
21,860
21,497
14,778
17,007
13,754
22,669
15,391
6,483
1,497
2,026
2,254
4,539
2,683
2,335
1,650
304
931
634
538
392
292
138
255
2551382923925386349313041,6502,3352,6834,5392,2542,0261,4976,48315,39122,66913,75417,00714,77821,49721,86011,0892,2352,2952,3202,1592,1072,0091,6421,4471,4541,4591,462
       Property Plant Equipment 
3
2
1
0
0
9
10
15
114
94
82
85
104
79
49
35
29
33
69
76
54
46
104
109
75
140
85
68
49
51
38
193
117
28
201
201281171933851496885140751091044654766933293549791048582941141510900123
       Goodwill 
15
14
12
11
9
8
7
49
38
27
16
0
0
0
0
0
149
111
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000111149000001627384978911121415
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,275
2,041
316
1,148
793
714
290
0
0
0
0002907147931,1483162,0412,2750000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
38
27
16,017
0
0
0
0
0
195
149
0
0
0
0
0
512
456
0
0
0
0
0
0
0
0
0
0
0000000000456512000001491950000016,017273800000000
       Long-term Assets Other 
1,444
1,443
1,441
1,436
1,633
1,992
2,090
2,095
2,169
1,807
1,774
10,347
21,003
25,513
367
381
0
0
0
0
0
0
0
0
0
0
0
0
0
862
768
0
175
110
54
541101750768862000000000000038136725,51321,00310,3471,7741,8072,1692,0952,0901,9921,6331,4361,4411,4431,444
> Total Liabilities 
46
32
38
52
32
44
97
121
167
162
142
365
325
371
318
312
4,289
1,720
4,998
2,339
2,022
2,421
2,862
2,464
1,874
1,866
1,803
1,549
1,577
5,806
4,581
4,864
3,123
12,070
104,400
104,40012,0703,1234,8644,5815,8061,5771,5491,8031,8661,8742,4642,8622,4212,0222,3394,9981,7204,28931231837132536514216216712197443252383246
   > Total Current Liabilities 
46
32
38
52
32
44
93
114
164
154
92
292
194
190
306
302
4,270
974
2,634
1,709
1,882
2,259
2,603
2,175
1,743
1,662
1,724
1,503
1,539
5,777
4,563
4,754
3,106
12,042
18,648
18,64812,0423,1064,7544,5635,7771,5391,5031,7241,6621,7432,1752,6032,2591,8821,7092,6349744,2703023061901942929215416411493443252383246
       Short-term Debt 
530
61
92
206
124
0
0
0
0
0
4,918
13,800
201
128
69
40
3,812
13,338
14
0
0
0
0
0
0
0
0
169
0
0
0
100
113
0
97
970113100000169000000001413,3383,812406912820113,8004,918000001242069261530
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
244
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,584
1,556
5,306
4,129
4,011
2,418
11,402
17,797
17,79711,4022,4184,0114,1295,3061,5561,58400000000000000024400000000000
       Other Current Liabilities 
-484
-29
-54
-154
-92
44
93
114
53
67
-63,993
-13,751
-135
-22
204
212
246
404
791
396
475
460
470
458
518
413
409
320
343
471
434
163
576
640
753
753640576163434471343320409413518458470460475396791404246212204-22-135-13,751-63,99367531149344-92-154-54-29-484
   > Long-term Liabilities 
0
0
0
0
0
0
4
7
3
8
50
73
131
182
12
10
19
746
2,365
630
141
161
259
289
130
204
79
46
38
29
17
110
17
28
85,752
85,752281711017293846792041302892591611416302,36574619101218213173508374000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
120
0
0
85,744
85,744001200000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
73
131
182
18
15
25
36
29
10
21
35
53
106
65
161
103
62
50
39
25
40
17
28
8
828174025395062103161651065335211029362515181821317300000000000
> Total Stockholder Equity
3,240
1,898
1,717
2,206
2,435
2,873
2,921
4,863
5,324
4,329
7,156
25,122
46,977
41,348
24,514
29,151
28,520
41,993
47,367
45,374
31,272
27,043
23,325
19,354
12,276
8,977
16,033
11,185
41,874
28,041
21,794
44,531
135,286
47,977
-5,759
-5,75947,977135,28644,53121,79428,04141,87411,18516,0338,97712,27619,35423,32527,04331,27245,37447,36741,99328,52029,15124,51441,34846,97725,1227,1564,3295,3244,8632,9212,8732,4352,2061,7171,8983,240
   Common Stock
2,238
1,806
1,806
2,181
2,396
2,496
2,558
2,808
2,948
3,058
10,719
26,805
50,230
50,345
32,939
33,836
25,290
24,612
28,132
31,733
30,970
32,613
41,013
40,317
36,005
37,146
41,296
40,210
75,196
72,286
79,154
111,384
234,148
235,277
320,884
320,884235,277234,148111,38479,15472,28675,19640,21041,29637,14636,00540,31741,01332,61330,97031,73328,13224,61225,29033,83632,93950,34550,23026,80510,7193,0582,9482,8082,5582,4962,3962,1811,8061,8062,238
   Retained Earnings 
-52
-663
-844
-925
-1,436
-1,498
-2,200
-3,289
-4,687
-6,668
-4,298
-3,074
-4,645
-10,388
-9,362
-5,658
2,168
2,841
12,750
13,283
3,202
-2,534
-14,158
-14,828
-17,562
-21,880
-21,764
-31,406
-37,076
-47,859
-60,271
-70,491
-124,124
-216,941
-359,368
-359,368-216,941-124,124-70,491-60,271-47,859-37,076-31,406-21,764-21,880-17,562-14,828-14,158-2,5343,20213,28312,7502,8412,168-5,658-9,362-10,388-4,645-3,074-4,298-6,668-4,687-3,289-2,200-1,498-1,436-925-844-663-52
   Capital Surplus 00000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000
   Other Stockholders Equity 
1,054
755
755
950
1,475
1,875
2,563
5,344
7,062
7,979
786
1,481
1,502
1,522
0
0
0
0
0
0
0
0
0
0
0
-6,679
-4,561
3,188
4,886
4,919
0
0
25,262
29,641
20,089
20,08929,64125,262004,9194,8863,188-4,561-6,679000000000001,5221,5021,4817867,9797,0625,3442,5631,8751,4759507557551,054



Balance Sheet

Currency in AUD. All numbers in thousands.